The Chemours Company $CC Stock Holdings Decreased by Private Management Group Inc.

Private Management Group Inc. decreased its holdings in The Chemours Company (NYSE:CC) by 15.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 642,364 shares of the specialty chemicals company’s stock after selling 117,978 shares during the period. Private Management Group Inc. owned 0.43% of Chemours worth $8,717,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Chemours in the second quarter worth about $34,000. Allworth Financial LP bought a new position in shares of Chemours during the 2nd quarter valued at approximately $51,000. State of Wyoming purchased a new position in shares of Chemours in the second quarter valued at $67,000. Nykredit A S bought a new stake in Chemours in the second quarter worth $99,000. Finally, Sterling Capital Management LLC raised its stake in Chemours by 839.3% during the third quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company’s stock valued at $69,000 after purchasing an additional 4,532 shares in the last quarter. 76.26% of the stock is owned by hedge funds and other institutional investors.

Chemours Stock Up 1.4%

Shares of NYSE CC opened at $13.46 on Wednesday. The Chemours Company has a 1 year low of $10.44 and a 1 year high of $28.67. The firm has a 50-day simple moving average of $13.87 and a two-hundred day simple moving average of $18.19. The company has a market cap of $2.03 billion, a P/E ratio of -13.20 and a beta of 1.47. The company has a debt-to-equity ratio of 24.25, a current ratio of 1.81 and a quick ratio of 0.98.

Chemours (NYSE:CC) last released its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. The business had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same period in the prior year, the company posted $0.40 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Research analysts anticipate that The Chemours Company will post 0.82 earnings per share for the current year.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 16th will be issued a dividend of $0.0875 per share. The ex-dividend date is Monday, November 16th. This represents a $0.35 dividend on an annualized basis and a yield of 2.6%. Chemours’s payout ratio is presently -34.31%.

Chemours News Roundup

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Stronger titanium dioxide pricing and growth in Advanced Performance Materials (APM) partly offset weak Thermal & Specialized Solutions (TSS) volumes in the third quarter. Zacks Q3 earnings report
• Negative Sentiment: Multiple law firms publicized a securities class action filed against Chemours and certain officers. The suit covers investors who acquired shares from February 20 through August 4, 2026, and alleges that the company misrepresented or failed to disclose weakening Opteon aftermarket demand while reaffirming its 2026 outlook. These are allegations, not established findings; the lead-plaintiff deadline is December 7. The litigation adds legal and reputational risk. Pomerantz class action announcement
• Negative Sentiment: Chemours’ third-quarter EPS of $0.21 fell short of the $0.26 analyst consensus, with weak TSS volumes weighing on results, despite revenue slightly exceeding expectations. Zacks Q3 earnings report
• Negative Sentiment: JPMorgan lowered its price target from $15 to $14 and maintained a Neutral rating, signaling more limited expected upside. JPMorgan rating information

Wall Street Analyst Weigh In

Several analysts have recently issued reports on CC shares. Mizuho cut shares of Chemours from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $18.00 to $15.00 in a research report on Wednesday, October 14th. Zacks Research downgraded Chemours from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 4th. Morgan Stanley set a $18.00 price objective on Chemours in a research note on Monday, August 10th. Barclays began coverage on Chemours in a report on Monday, October 12th. They issued an “equal weight” rating and a $16.00 target price for the company. Finally, JPMorgan Chase & Co. cut their target price on Chemours from $15.00 to $14.00 and set a “neutral” rating on the stock in a research report on Monday. Three analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.36.

Chemours Profile

The Chemours Company is a global chemicals manufacturer spun off from DuPont in 2015 and headquartered in Wilmington, Delaware. It develops and produces materials used in industries ranging from construction and transportation to electronics and energy. Chemours’ Titanium Technologies business makes titanium dioxide (TiO₂) pigment, sold under the Ti-Pure brand, which is used to add whiteness, brightness and opacity to products such as paints, coatings, plastics and paper. Its Thermal & Specialized Solutions business supplies refrigerants, foam-blowing agents and other specialty fluids, including products marketed under the Opteon and Freon brands.